May 1st 2024
C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Once-Weekly Carfilzomib Regimen Approved by the FDA for Myeloma
October 1st 2018A once-weekly dosing option of carfilzomib (Kyprolis) has been approved by the FDA for use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma, Amgen, the manufacturer of the agent, has announced.<br />
Read More
Immunotherapy Combination Treatment Options Growing in R/R Multiple Myeloma Space
September 25th 2018Sham Mailankody, MBBS, discusses current treatment options and shifting preferences, especially toward triplet combinations, for patients with relapsed/refractory multiple myeloma, as well as emerging immunotherapy treatment options.
Read More
Targeted Oncology Launches its Latest Virtual Tumor Board on Multiple Myeloma
September 20th 2018<em>Targeted Oncology</em>™ will launch its third “Expert Perspective: Virtual Tumor Board” on Monday, September 24. Each Virtual Tumor Board is a video-editorial discussion that features key opinion leaders from a specific oncological field considering options for treating patients based on case scenarios. This episode will focus on multiple myeloma.
Read More
Selinexor/Dexamethasone Combo Shows Promising Activity in Penta-Refractory Myeloma
September 15th 2018The combination of selinexor and dexamethasone induced an overall response rate of 26.2% and a median overall survival of 8.6 months in patients with penta-refractory multiple myeloma, according to phase IIb results presented at the 2018 SOHO Annual Meeting.
Read More
Safety of Carfilzomib Combinations Confirmed in Multiple Myeloma
September 14th 2018Consistent benefit was seen with carfilzomib (Kyprolis)-based regimens across subgroups of patients with multiple myeloma in the ASPIRE and ENDEAVOR trials, according to updated safety data reported at the 2018 SOHO Annual Meeting.
Read More